Mereo BioPharma Group Ownership | Who Owns Mereo BioPharma Group?
Mereo BioPharma Group Ownership Summary
Mereo BioPharma Group is owned by 14.13% institutional investors, 1.03% insiders, and 84.85% retail investors. Janus henderson group is the largest institutional shareholder, holding 2.22% of MREO shares. UBS (Lux) EF Biotech (USD) P-acc is the top mutual fund, with 0.55% of its assets in Mereo BioPharma Group shares.
MREO Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | Mereo BioPharma Group | 14.13% | 1.03% | 84.85% |
Sector | Healthcare Stocks | 57.47% | 9.40% | 33.13% |
Industry | Biotech Stocks | 69.06% | 8.93% | 22.01% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Janus henderson group | 17.12M | 2.22% | $59.84M |
Rubric capital management lp | 15.31M | 1.99% | $53.58M |
Rock springs capital management lp | 9.60M | 1.25% | $33.60M |
Adage capital partners gp | 8.72M | 1.13% | $30.50M |
Mangrove partners | 8.64M | 1.12% | $30.23M |
Deerfield management company, l.p. (series c) | 6.71M | 0.87% | $23.49M |
Frazier life sciences management | 4.40M | 0.63% | $15.84M |
Alkeon capital management | 4.70M | 0.61% | $16.44M |
683 capital management | 4.55M | 0.59% | $15.93M |
Millennium management | 3.97M | 0.51% | $13.88M |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Tejara capital | 2.32M | 5.31% | $8.11M |
Mangrove partners | 8.64M | 3.34% | $30.23M |
Acuta capital partners | 779.31K | 2.74% | $2.73B |
Great point partners | 1.15M | 1.90% | $4.03M |
Clearline capital lp | 3.22M | 1.49% | $11.26M |
Rock springs capital management lp | 9.60M | 1.28% | $33.60M |
683 capital management | 4.55M | 0.99% | $15.93M |
Frazier life sciences management | 4.40M | 0.74% | $15.84M |
Rubric capital management lp | 15.31M | 0.69% | $53.58M |
Healthinvest partners ab | 390.00K | 0.65% | $1.37M |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Janus henderson group | 17.12M | 0.03% | 4.78M |
Frazier life sciences management | 4.40M | 0.74% | 4.40M |
Ubs group | 2.65M | 0.00% | 2.65M |
Great point partners | 1.15M | 1.90% | 1.15M |
Ubs asset management americas | 964.90K | 0.00% | 964.90K |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Millennium management | 3.97M | 0.01% | -1.43M |
Morgan stanley | 207.74K | 0.00% | -1.17M |
Adage capital partners gp | 8.72M | 0.05% | -1.00M |
Price t rowe associates inc /md/ | - | - | -991.97K |
Tejara capital | 2.32M | 5.31% | -512.90K |
New Positions
Holder | Shares | % Assets | Change | Value |
---|---|---|---|---|
Frazier life sciences management | 4.40M | 0.74% | 4.40M | $15.84M |
Ubs group | 2.65M | 0.00% | 2.65M | $9.27M |
Great point partners | 1.15M | 1.90% | 1.15M | $4.03M |
Ubs asset management americas | 964.90K | 0.00% | 964.90K | $3.38M |
Woodline partners lp | 618.78K | 0.01% | 618.78K | $2.17M |
Sold Out
Holder | Change |
---|---|
Plante moran financial advisors | -48.00 |
Quadrant capital group | -398.00 |
Tower research capital llc (trc) | -645.00 |
Ica group wealth management | -1.00K |
Point72 asset management | -1.90K |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Dec 31, 2024 | 93 | 14.81% | 108,788,635 | 2.89% | 14 | 0.30% | 38 | 18.75% | 26 | 23.81% |
Sep 30, 2024 | 81 | - | 105,735,860 | 5.18% | 68 | 33.31% | 32 | -8.57% | 21 | -22.22% |
Jun 30, 2024 | 80 | -4.76% | 100,517,090 | 19.63% | 14 | 8870446.46% | 34 | -33.33% | 27 | 125.00% |
Mar 31, 2024 | 84 | 25.37% | 84,026,001 | 6.98% | - | 0.00% | 51 | 34.21% | 12 | 9.09% |
Dec 31, 2023 | 67 | 17.54% | 78,543,746 | 11.37% | 65 | 1.91% | 38 | 100.00% | 11 | -35.29% |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
UBS (Lux) EF Biotech (USD) P-acc | 855.00K | 0.55% | 336.80K |
HealthInvest Sustainable Healthcare E | 270.00K | 0.17% | - |
Tema Obesity & Cardiometabolic ETF | 267.46K | 0.17% | - |
Tema Oncology ETF | 261.68K | 0.17% | - |
iShares Genomics Immnlgy & Hlthcr ETF | 246.60K | 0.16% | - |
abrdn Life Sciences Investors | 160.38K | 0.10% | 160.38K |
UBS Global Equity Biotech | 128.03K | 0.08% | 128.03K |
HealthInvest Alpha Fund C | 120.00K | 0.08% | 120.00K |
Alger LIfe Sciences Innovation Composite | 102.58K | 0.07% | -84.07K |
Fidelity Nasdaq Composite Index | 92.16K | 0.06% | - |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Sep 13, 2024 | Scots-Knight Denise | Chief Executive Officer | Sell | $253.45K |
Sep 12, 2024 | Scots-Knight Denise | Chief Executive Officer | Sell | $127.97K |
Sep 12, 2024 | Lewicki John A. | Chief Scientific Officer | Sell | $23.31K |
Sep 13, 2024 | Lewicki John A. | Chief Scientific Officer | Sell | $46.17K |
Sep 12, 2024 | Sermon Charles | General Counsel | Sell | $44.64K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2025 Q1 | - | - |
2024 Q3 | - | 13 |
2024 Q2 | - | 12 |
2024 Q1 | - | - |
MREO Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools